Mayer Ramona, Mock Ulrike, Jäger Robert, Pötter Richard, Vutuc Christian, Eiter Helmut, Krugmann Kristine, Hammer Josef, Hirn Brigitte, Hawliczek Robert, Knocke-Abulesz Tomas-Henrik, Lukas Peter, Nechville Elisabeth, Pakisch Brigitte, Papauschek Michael, Raunik Wolfgang, Rhomberg Walter, Sabitzer Hubert, Schratter-Sehn Annemarie, Sedlmayer Felix, Wedrich Irene, Auberger Thomas
Dept. of Radiation Oncology, Medical University of Graz, Austria.
Radiother Oncol. 2004 Dec;73 Suppl 2:S24-8. doi: 10.1016/s0167-8140(04)80008-2.
The planned MedAustron hadron therapy facility is designed to compare proton and carbon ion beam therapy under the same technical conditions. For the calculation of the number of potential patients for hadron therapy so far, only epidemiological estimations on cancer incidence are available without inclusion of the percentage of patients routinely referred to conventional radiotherapy.
Nationwide prospective survey to collect disease and treatment related data on patients receiving conventional radiotherapy at all 12 treatment facilities. Epidemiological cancer incidence (Statistic Austria 1999) were correlated with the number of patients receiving conventional radiotherapy. Based on published clinical and experimental results on proton and carbon ion therapy, a calculation of patient's subgroups suitable for hadron therapy was performed at five European University hospitals involved in the HICAT, CNAO, ETOILE and MEDAustron project. Using the mean values of the University specific percentages per tumour site, the number of potential patients was estimated.
In Austria, a total of 3783 patients started radiotherapy during the study period of 3 months resulting in an approximated number of 15132 patients per year. The number of potential patients was estimated to 2044 per year, representing 5.6% of all newly diagnosed cancer patients and 13.5% of all irradiated cancer patients.
There is a clear place for a hadron therapy facility in Austria, based on pattern of care in radiotherapy, cancer incidence and indications.
计划中的MedAustron强子治疗设施旨在在相同技术条件下比较质子和碳离子束治疗。到目前为止,在计算强子治疗的潜在患者数量时,仅可获得癌症发病率的流行病学估计,未纳入常规转诊至传统放疗的患者百分比。
在全国范围内进行前瞻性调查,以收集所有12个治疗机构中接受传统放疗患者的疾病和治疗相关数据。将癌症发病率的流行病学数据(奥地利统计局,1999年)与接受传统放疗的患者数量相关联。基于已发表的关于质子和碳离子治疗的临床和实验结果,对参与HICAT、CNAO、ETOILE和MedAustron项目的五家欧洲大学医院中适合强子治疗的患者亚组进行了计算。利用每个肿瘤部位各大学特定百分比的平均值,估计了潜在患者数量。
在奥地利,在3个月的研究期间共有3783名患者开始接受放疗,每年的患者数量约为15132名。估计每年的潜在患者数量为2044名,占所有新诊断癌症患者的5.6%,占所有接受放疗癌症患者的13.5%。
基于放疗的治疗模式、癌症发病率和适应症,奥地利有必要建立一家强子治疗设施。